About Us

Letter from the CEO Business Overview Business History Core Networks C.I Introduction

Letter from the CEO

HOME > About us > Letter from the CEO

CEO
Mi Won SOHNCEO of MTHERA PHARMA

“ Nature meets Science ”

Hello, everyone.
Welcome to our website!
This is Mi Won SOHN, CEO of MTHERA PHARMA.

MTHERA PHARMA was established in February 2020. By collaborating with world renowned scholars of Korea, we developed expertise in multi-component and multi-targeting (MCMT) approach and cutting-edge CMC technology.

We strive to be a more global pharmaceutical R&D company by pursuing health and happiness of mankind through development of new medicine for chronic diseases.

We look forward to your support and attention. Thank you.

Hello, everyone.

I am Mi Won SOHN, CEO of MTHERA PHARMA.

MTHERA PHARMA is a venture pharmaceutical company dedicated to
pursuing the health and happiness of humanity.

We are striving to secure global competitiveness through the development of
multi-target natural product-based new drugs capable of treating chronic,
intractable diseases with complex etiologies.

As a pharmaceutical venture, we are building the essential elemental
technologies required for drug development. Through our domestic
and international networks, we aim to exchange ideas and secure
knowledge with world-class scholars, growing into Korea's leading
sustainable global company in this field.

As we head into 2026, MTHERA PHARMA is poised to create a new turning
point and take a great leap forward.

We look forward to your support and attention.

Thank you.

“ Nature meets Science ”

CEO
Mi Won SOHN, PH.D

Who is the CEO?

Profile

Graduated College of Pharmacy, Seoul National University
Dong-A Pharm / Dong-A ST Co., Ltd.
- Executive Director of R&D Center / Head of R&D Planning
Office of Strategic R&D Planning(Ministry of Knowledge Economy)
- Director of Natural Product Drug Development Division

Public Advisory & Policy Consultation

Member, Basic and Source Material Development Committee, Ministry of Science and ICT(MSIT) (2023–Present)
Member, Research Review Committee, Korea Institute of Science and Technology(KIST) (2024–Present)
Chairperson, Industry Committee, Association of Korean Woman Scientists and Engineers(KWSE) (2024–2025)
Steering Committee Member, Bio & Medical Technology Development Project, Ministry of Science and ICT(MSIT) (2021–2025)
Member, Health and Medical Technology Policy Review Committee(2021–2023)
Advisor, Health and Medical Technology Policy Review Committee(2020–2022)
Advisor, Presidential Advisory Council on Science and Technology(PACST) (2019–2020)

Product Development

Domestic

Stillen(No. 1 botanical drug in domestic sales, peak annual sales of 90 billion KRW)
- Pharmacological research
Motilitione(Gastroprokinetic agent, annual sales exceeding 20 billion KRW)
- Principal Investigator(PI)

Global

DA-9801(Treatment for diabetic neuropathy, successful US Phase 2 clinical trials): Head of R&D
DA-9805(Treatment for Parkinson’s disease, initiation of US Phase 3 clinical trials): Head of R&D
DA-9803(Treatment for dementia, global preclinical studies in progress): Head of R&D

Awards & Honors

2017. 12. 20 “Woman Scientist of The Year” (Ministry of Science and ICT)
2016. 05. 19 Presidential Citation
2015. 10. 29 The 69th IR52 Jang Young-Shil Award